User profiles for Mark J. Mulligan
 | Mark J. Mulligan, MD, FIDSANew York University Vaccine Center Verified email at nyulangone.org Cited by 25106 |
[HTML][HTML] Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
…, S Lockhart, K Neuzil, MJ Mulligan… - … England Journal of …, 2020 - Mass Medical Soc
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …
[HTML][HTML] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
…, SC Morpeth, A Mourad, MJ Mulligan… - Nature …, 2021 - nature.com
Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs)
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
on hydroxychloroquine/chloroquine, which currently face recruitment challenges or …
[HTML][HTML] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman… - Nature, 2020 - nature.com
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
[HTML][HTML] Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
…, H Janes, ST Karuna, MJ Mulligan… - … England Journal of …, 2013 - Mass Medical Soc
Background A safe and effective vaccine for the prevention of human immunodeficiency
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime–…
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime–…
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo …
…, I Skountzou, RW Compans, MJ Mulligan… - The Lancet, 2017 - thelancet.com
Background Microneedle patches provide an alternative to conventional needle-and-syringe
immunisation, and potentially offer improved immunogenicity, simplicity, cost-effectiveness, …
immunisation, and potentially offer improved immunogenicity, simplicity, cost-effectiveness, …
[PDF][PDF] Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
[HTML][HTML] Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
…, KM Neuzil, W Hahn, J Hunt, MJ Mulligan… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
[HTML][HTML] Homologous and heterologous Covid-19 booster vaccinations
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …
have received emergency use authorization in the United States are highly effective, …
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
…, M Dittmann, MI Samanovic, MJ Mulligan… - Science translational …, 2021 - science.org
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat
for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies …
for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies …
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection
The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of
reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and …
reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and …